About this trial

The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed.

Participants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.

Eligibility criteria

Qualifiers

Participants aged 45 years or older

Participants who are willing and able to provide written informed consent and adhere to study procedures

Participants presenting with visible and/or non-visible haematuria within 6 months prior to study enrollment

Participants scheduled to undergo standard of care cystoscopy for urinary bladder examination within 60 days after study enrollment

Disqualifiers

Participants with history of urothelial cancer in the bladder and/or upper urinary tract

Participants who had prior cystoscopy for haematuria within the past 2 years

Participants previously enrolled in this study

Participants treated for prostate cancer within the last 12 months

Trial design

Treatments tested in this trial

  • Bladder EpiCheck

Treatment groups

800 Participants
are divided into 1 treatment group

Locations

5
NHS FifeKY12 OSU, DunfermlineFife, United Kingdom
Addenbrooke's Hospital Cambridge United Kingdom
NHS Lothian Edinburgh United Kingdom
Guy's and St Thomas London United Kingdom

Sponsors and collaborators

Nucleix Ltd.

Lead sponsor